In Vitro: 6-Hydroxy-DOPA (0~20 μM; U20S cells) selectively inhibits RAD52-mediated recombination. 6-Hydroxy-DOPA (0~10 μM; HEK293T cells) decreases the number of eGFP-RAD52 foci in a dose-dependent manner. 6-Hydroxy-DOPA (5~75 μM; HCC1937 cells) selectively reduces the viability of the BRCA1-deficient triple-negative breast cancer cell line HCC1937.